| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
study archive
with methacholine |
Lung, respiratory function, baseline and methacholine-challenged (several doses). | QTL population | f | 7-8wks | 2005 |
|
|
ventilator
with methacholine |
Airway resistance. Baseline vs. methacholine-challenged (several doses). | inbred (37) | both | 9-12wks | 2010 |
|
|
plethysmography
with methacholine |
Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). | inbred (29) | both | 9-12wks | 2010 |
|
|
ventilator
with methacholine |
Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). | inbred (29) | both | 9-12wks | 2010 |
|
|
monitoring system
with morphine |
Induced respiratory depression, time to recovery (for mice that survived), survival data (for mice that did not survive). | inbred w/CC8 (8) | both | 8-24wks | 2020 |
|
|
study archive
with ethanol |
Sensitivity to ethanol. Baseline and ethanol. | QTL population | both | 9-34wks | 2012 |
|
|
balance beam
with ethanol |
Ethanol i.p. (several doses) vs. control (saline). Missteps count. 3 beam lengths. | inbred (8) | both | 8wks | 2003 |
|
|
grid test
with ethanol |
Ethanol injection (several doses) vs. control (saline). Grid habituation, missteps rate. | inbred (8) | both | 8wks | 2003 |
|
|
rotarod
with diazepam |
Latency to fall from 5 rpm rotarod immediately after diazepam injection. | inbred (15) | both | 6-7wks | 1998 |
|
|
drug and metabolite quantification
with diazepam |
Diazepam (and metabolite) concentration in brain tissue immediately after diazepam injection and rotarod. | inbred (15) | both | 6-7wks | 1998 |
|
|
monitoring system
with diazepam |
Locomotor activity. Baseline vs. immediately after Diazepam injection (several doses). 15 min test. | inbred (15) | both | 6-7wks | 1998 |
|
|
body temperature
with diazepam |
Baseline vs. 30 min after diazepam injection (several doses). | inbred (15) | both | 6-7wks | 1998 |
|
|
rotarod
with ethanol |
Baseline and ethanol i.p. 3 fixed speeds (several doses) and accelerating. | inbred (22) | both | 9-17wks | 2003 |
|
|
dowel balance test
with ethanol |
Latency to fall 0 min and 30 min post-injection, 2 widths. Ethanol 2 g/kg. | inbred (21) | both | 9-17wks | 2003 |
|
|
vertical wire mesh
with ethanol |
Latency to fall 30 min post-injection. Ethanol 2 g/kg i.p. | inbred (21) | both | 9-17wks | 2003 |
|
|
grip strength
with ethanol |
Baseline vs. 30 min after ethanol 2 g/kg i.p. | inbred (21) | both | 9-17wks | 2003 |
|
|
parallel rod floor test
with ethanol |
Parallel rod balance test, baseline vs. ethanol 2 g/kg i.p.. | inbred (8) | both | 7-14wks | 2005 |
|
|
body weight
with haloperidol |
Baseline vs. after haloperidol 60d implant. | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
drug and metabolite quantification
with haloperidol |
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
inclined screen test
with haloperidol |
Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
open field test
with haloperidol |
Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
behavior observation
with haloperidol |
Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
bottle choice test | Palatable food consumption, preference for Boost solution. | CC w/par (18) | both | 10-39wks | 2023 |
|
|
open field test
with cocaine |
Distance traveled, habituation ratio, number of rears, ambulatory time, time in perimeter, corners, and center; cocaine sensitization. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
operant conditioning chamber
with cocaine |
Number of infusions, active lever presses, inactive lever presses, intravenous self administration, reversal learning. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
bottle choice test
with ethanol |
Voluntary consumption of ethanol, and ethanol with saccharin (several doses in water). | inbred (22) | both | 8-12wks | 2007 |
|
|
electroconvulsion test
with lamotrigine |
Electroconvulsive thresholds. Lamotrigine. 2 test sites. | inbred (16) | both | 6-11wks | 2000 |
|
|
tail suspension test
with imipramine |
Immobility. Baseline (saline) vs. imipramine i.p. 6 min test. | inbred (12) | m | 5-10wks | 2003 |
|
|
light-dark box
with imipramine |
Anxiety-related behavior. Baseline (saline) vs. imipramine i.p. 10 min test. | inbred (12) | m | 5-10wks | 2003 |
|
|
open field test
with imipramine |
Locomotor activity, exploratory and anxiety-related behavior. Baseline (saline) vs. imipramine i.p. | inbred (12) | m | 5-10wks | 2003 |
|
|
forced swim test
with lithium |
Lithium (several doses) vs. control. 6 min test. | inbred (11) | m | 7-8wks | 2011 |
|
|
drug and metabolite quantification
with lithium |
Lithium concentration in brain tissue and blood serum after lithium (several doses). | inbred (11) | m | 7-8wks | 2011 |
|
|
drug and metabolite quantification
with nicotine |
Amount of nicotine and cotinine in blood plasma after nicotine doses. High and lower doses. | inbred (8) | m | 8-12wks | 2011 |
|
|
behavior observation
with nicotine |
Observed measures of anxiety. Nicotine (high dose) vs. control. 20 min period. | inbred (8) | m | 8-12wks | 2011 |
|
|
elevated plus maze
with nicotine |
Measures of anxiety. Nicotine (high dose) vs. control. 5 min test. | inbred (8) | m | 8-12wks | 2011 |
|
|
fear conditioning test
with nicotine |
Contextual fear, cued fear. Nicotine (high and several lower doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
behavior observation
with nicotine |
Observed measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
elevated plus maze
with nicotine |
Measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
fear conditioning test
with nicotine |
Contextual fear, cued fear during nicotine withdrawal. Nicotine (high and several lower doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
conditioned place preference test
with nicotine |
Nicotine preference and learning effect. Nicotine-treated vs. control. 2 trials (day 5, day 10). | inbred (8) | m | 8-10wks | 2014 |
|
|
histopathology
with ENU |
Tumor growth frequency rates. ENU mutagen 100 mg/kg vs. control. | inbred (20) | both | 9wks; 12-64wks | 2006 |
|
|
body weight
with isoniazid |
Body weight. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
organ weights
with isoniazid |
Body, liver, kidney weights. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
metabolic panel
with isoniazid |
Alanine transaminase. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
lipid profile
with isoniazid |
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
histopathology
with isoniazid |
Liver pathology scores. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
body weight
with DB289 |
DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
metabolic panel
with DB289 |
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
urinalysis
with DB289 |
Urine volume, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
biomarker quantification
with DB289 |
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
organ weights
with DB289 |
Kidney and liver weights. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
drug and metabolite quantification
with DB289 |
Kidney metabolite (DB75) concentration. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
operant conditioning chamber
with cocaine |
Intravenous self-administration of cocaine via activation of levers, and locomotor activity. | BXD (4) | both | 8-17wks | 2013 |
|
|
histopathology
with cadmium |
Cadmium-induced toxicity to liver, testis, trigeminal ganglia. | inbred (8) | m | 8wks | 2001 |
|
|
study archive
with cocaine |
Open field test. Locomotor, anxiety-related, circadian behavior. Baseline and after cocaine i.p. | QTL population | both | 10-14wks | 2014 |
|
|
body weight
with atenolol, isoproterenol |
Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
organ weights
with atenolol, isoproterenol |
Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
tail cuff
with atenolol, isoproterenol |
Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
ECG
with atenolol, isoproterenol |
Heart rate and wave amplitudes and intervals. Unconscious. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
behavior observation
with ethanol |
Observed gait, hindlimb splay 10 min and 30 min after ethanol i.p. (several doses). | inbred (9) | both | 8-11wks | 2004 |
|
|
open field test
with ethanol |
Locomotor activity. Ethanol i.p. (several doses) vs. control (saline i.p.). 45s test. | inbred (9) | both | 8-11wks | 2004 |
|
|
behavior observation
with ethanol |
Ethanol withdrawal severity and handling-induced convulsions. | inbred (15) | m | 8-11wks | 2005 |
|
|
open field test
with methamphetamine |
Locomotor activity and habituation. Baseline (saline) vs. methamphetamine 2 mg/kg i.p. 30 min test. | B6.A consomic w/par (21) | both | 10wks | 2008 |
|
|
metabolic panel
with trichloroethylene |
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum). Baseline and trichloroethylene-exposed (several timepoints). No fast. | inbred (17) | m | 7wks | 2010 |
|
|
drug and metabolite quantification
with trichloroethylene |
Trichloroethylene metabolites in serum, 2h, 4h, 24h after trichoroethylene exposure. | inbred (17) | m | 7wks | 2010 |
|
|
metabolic panel
with high-fat diet and ethanol |
Alanine transaminase (serum) after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
alcohol quantification
with high-fat diet and ethanol |
Alcohol concentration in blood and urine after 4 wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
organ weights
with high-fat diet and ethanol |
Liver weight after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
histopathology
with high-fat diet and ethanol |
Liver histopathology, injury after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
metabolite quantification
with high-fat diet and ethanol |
Homocysteine concentration after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
lipid profile
with high-fat diet and ethanol |
Hepatic triglycerides after 4wk regimen of ethanol and high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
RNA expression profiling
with high-fat diet and ethanol |
Liver gene expression after 4wk regimen of ethanol and high-fat diet. 24h fast. mRNA abundance relative to the control (high-fat only) group. | inbred (14) | m | 8-14wks | 2011 |
|
|
organ weights
with trichloroethylene |
Liver, kidney weights. Trichloroethylene-exposed vs. control. | inbred (7) | m | 6-7wks | 2014 |
|
|
metabolic panel
with trichloroethylene |
Blood urea nitrogen (serum). Trichloroethylene-exposed vs. control. | inbred (7) | m | 6-7wks | 2014 |
|
|
drug and metabolite quantification
with trichloroethylene |
Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. | inbred (7) | m | 6-7wks | 2014 |
|
|
RNA expression profiling
with trichloroethylene |
Trichloroethylene effect on mRNA gene expression in liver and kidney, relative to controls. | inbred (7) | m | 6-7wks | 2014 |
|
|
histopathology
with trichloroethylene |
Kidney histopathology evaluation after trichloroethylene exposure, relative to controls. | inbred (7) | m | 6-7wks | 2014 |
|
|
health assessment
with pilocarpine |
Study of pilocarpine effect on epilepticus seizures. | inbred (11) | m | 8-10wks | 2012 |
|
|
bronchoalveolar lavage assessment
with ovalbumin |
Lung inflammatory changes. Ovalbumin vs. control. | inbred (8) | m | 6-8wks | 2001 |
|
|
RNA expression profiling
with selenium |
Selenium regulation of selenoprotein enzyme activity and transcripts. | inbred w/CC8 (8) | m | 3-14wks | 2018 |
|
|
open field test
with cocaine |
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. | inbred (45) | m | 8-11wks | 2015 |
|
|
open field test
with cocaine |
Locomotor activity. Baseline (saline) vs. cocaine i.p. (several doses). 1.3h and 2.3 h duration. | inbred (15) | both | 8-10wks | 2011 |
|
|
open field test
with R-6-Br-APB, quinelorane |
Locomotor activity. Baseline (saline) vs. dopamine agonists i.p. (several doses). 3h session. | inbred (15) | both | 8-10wks | 2011 |
|
|
metabolic panel
with acetaminophen |
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
histopathology
with acetaminophen |
Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolite quantification
with acetaminophen |
Liver protein homeostasis. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
biomarker quantification
with acetaminophen |
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
organ weights
with acetaminophen |
Liver weight after acetaminophen (several doses) vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolic panel
with acetaminophen |
Alanine transaminase (serum). Acetaminophen (several doses) vs. control. | inbred (5) | m | 6-8wks | 2005 |
|
|
metabolite quantification
with acetaminophen |
Glutathione. | inbred (5) | m | 6-8wks | 2005 |
|
|
drug and metabolite quantification
with acetaminophen |
Acetaminophen metabolite concentrations (serum) and liver protein homeostasis. Baseline vs. acetaminophen (several doses, several timepoints). | inbred (5) | m | 6-8wks | 2005 |
|
|
histopathology
with acetaminophen |
Liver histopathology, necrosis, injury after acetaminophen vs. control. 18h fast. | inbred (5) | m | 6-8wks | 2005 |
|
|
tail suspension test
with fluoxetine |
Immobility. Fluoxetine-treated vs. control. 5 min test. | inbred (30) | m | 9-11wks | 2011 |
|
|
open field test
with fluoxetine |
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. | inbred (30) | m | 9-11wks | 2011 |
|
|
drug and metabolite quantification
with fluoxetine |
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. | inbred (30) | m | 9-11wks | 2011 |
|
|
biomarker quantification
with fluoxetine |
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. | inbred (30) | m | 10-11wks | 2011 |
|
|
immune cell quantification
with BEZ235, doxorubicin, idarubicin, selumetinib |
In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. | inbred w/CC7 (36) | m | 10wks | 2015 |
|
|
inclined screen test | Latency to move all four paws. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
open field test | Locomotor activity, anxiety, stereotypy. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
behavior observation | Vacuous chewing, tongue protrusion, jaw tremor. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
body weight
with arsenic |
Baseline, then after iAs exposure for 26 wks | DO population | m | 4-34 wks | 2022 |
|
|
intake monitoring
with arsenic |
Food and water consumption, at baseline then at 1 to 4 wk intervals after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
MRI
with arsenic |
Fat and lean tissue mass at baseline, and 12 and 24 wks after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
urinalysis
with arsenic |
Urine volume at baseline, and 12 and 24 wks after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
metabolic panel
with arsenic |
Blood glucose following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
hormone quantification
with arsenic |
Blood insulin following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure | DO population | m | 4-34 wks | 2022 |